FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

9 letters match. Newest first.

  1. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  2. Jabil Inc.

    FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.

    High risk
  3. Eugia Pharma Specialities Limited

    FDA warned Eugia Pharma Specialities that flawed aseptic line design and poor aseptic practices at its Kolthur Village plant risk contaminating sterile injectables.

    High risk
  4. Fareva Amboise

    FDA warned Fareva Amboise in France about sterile drug manufacturing failures, including aseptic practice and data integrity problems.

    High risk
  5. Wizcure Pharmaa Private Limited

    FDA warned Wizcure Pharmaa about serious manufacturing and data-integrity failures in sterile OTC drugs.

    High risk
  6. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  7. CareFusion 213, LLC

    FDA warns CareFusion 213 over inadequate investigations and contamination controls at its El Paso sterile drug plant.

    High risk
  8. Par Health USA, LLC & Endo USA, Inc.

    FDA cited Par Health USA/Endo USA’s Rochester plant for sterile injectable contamination-control, media fill, and visual inspection failures after an October 2025 inspection.

    High risk
  9. MAST Biosurgery USA, Inc.

    MAST Biosurgery USA never ran promised endotoxin tests on its SurgiWrap FROST surgical mesh and failed to report patient injuries, FDA says.

    High risk